ter Haar, E. L. M. http://orcid.org/0000-0001-9874-4670
Thomas, S. E. http://orcid.org/0000-0002-1343-353X
van den Reek, J. M. P. A. http://orcid.org/0000-0002-3642-2673
Otero, M. E. http://orcid.org/0000-0003-0191-3293
Njoo, M. D. http://orcid.org/0000-0003-1424-5722
Ossenkoppele, P. M. http://orcid.org/0000-0002-7311-7213
Kop, E. N.
Dodemont, S. R. P. http://orcid.org/0000-0001-5395-5925
Körver, J. E. M.
Kuijpers, A. L. A. http://orcid.org/0000-0001-7874-1165
Lindhout, R. J.
Tupker, R. A. http://orcid.org/0000-0003-2378-3741
Mommers, J. M. http://orcid.org/0000-0002-4930-4107
Berends, M. A. M. http://orcid.org/0000-0003-3851-1407
Koetsier, M. I. A. http://orcid.org/0000-0002-7823-8380
de Bruin-Weller, M. S. http://orcid.org/0000-0002-1249-6993
Visch, M. B. http://orcid.org/0000-0001-6265-3830
Arnold, W. P. http://orcid.org/0000-0002-7267-7825
van Lümig, P. P. M. http://orcid.org/0000-0001-6619-0853
Kleinpenning, M. M.
Lubeek, S. F. K. http://orcid.org/0000-0003-2694-6059
de Jong, E. M. G. J. http://orcid.org/0000-0003-3872-5704
Article History
Accepted: 8 June 2022
First Online: 21 July 2022
Declarations
:
: E.L.M. ter Haar has carried out investigator-initiated research with financial support from Almirall and has carried out clinical trials for Novartis. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen (Radboudumc), The Netherlands. S.E. Thomas carries out clinical trials for Janssen and Novartis. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands. M.E. Otero has acted as a consultant for Eli Lilly. P.P.M. van Lümig has received research funding from Wyeth; has carried out clinical trials for Abbott and Janssen-Cilag; has received speaking and consulting fees from Wyeth and Schering-Plough; has received reimbursement for attending a symposium from Schering-Plough and Pfizer; and has attended advisory boards for Abbvie, Leo Pharma, Novartis and UCB. W.P. Arnold has been a consultant, advisory board member, and/or speaker for AbbVie and UCB. S.R.P. Dodemont has attended advisory boards for Abbvie, Janssen and Leo Pharma, and has received a congress fee from Abbvie. M.S. de Bruin-Weller has been a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Arena, Aslan, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme. R.A. Tupker has attended advisory boards for Leo Pharma, UCB Pharma, and Eli Lilly Netherlands. E.M.G.J. de Jong has received research grants for the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands, from AbbVie, BMS, Janssen Pharmaceutica, Leo Pharma, Novartis, and UCB for research on psoriasis; has acted as a consultant and/or paid speaker for, and/or participated in research sponsored by, companies that manufacture drugs used for the treatment of psoriasis or eczema, including AbbVie, Amgen, Almirall, Celgene, Galapagos, Janssen Pharmaceutica, Lilly, Novartis, Leo Pharma, Sanofi and UCB. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands. J.M.P.A. van den Reek has carried out clinical trials for AbbVie, Celgene and Janssen; has received speaking fees/attended advisory boards from AbbVie, Janssen, BMS, Almirall, LEO Pharma, and Eli Lilly; and has received reimbursement for attending a symposium from Janssen, Pfizer, Celgene, and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands. S.F.K. Lubeek has received research grants for investigator-initiated research by Almirall, and has acted as a consultant and/or paid speaker for Janssen, LEO Pharma, Almirall, Sanofi Genzyme, and Sunpharma. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Centre Nijmegen, The Netherlands. M.D. Njoo, P.M. Ossenkoppele, E.N. Kop, J.E.M. Körver, A.L.A. Kuijpers, R.J. Lindhout, J.M. Mommers, M.A.M. Berends, M.I.A. Koetsier, M.B. Visch, and M.M. Kleinpenning have no conflicts of interest to report.
: BioCAPTURE was funded by the University Medical Center St Radboud Foundation. This foundation received funding from Pfizer, Janssen, Novartis, LEO Pharma, AbbVie, Almirall, Eli Lilly, and UCB. All decisions regarding the design and execution of this study, data collection, data management, data analysis, interpretation of the data, manuscript preparation, manuscript review, or manuscript approval were made independently from industrial contributions.
: Ethical review and approval were waived for this study in consultation with our regional Medical Ethics Committee due to the non-interventional design of the study.
: Informed consent was not necessary due to the non-interventional design of this study; however, written informed consent is obtained from every patient included in the study.
: Not applicable (see the Consent to participate section).
: The data that support the findings of this study are not publicly available as participants of this study did not agree for their data to be shared publicly.
: Not applicable.
: Conceptualization: ELMtH, SET, JMPAvdR, EMGJdJ and SFKL. Methodology: ELMtH, SET, JMPAvdR, EMGJdJ and SFKL. Software: ELMtH, SET and JMPAvdR. Validation: JMPAvdR, EMGJdJ and SFKL. Formal analysis: ELMtH, SET and JMPAvdReek. Investigation: ELMtH and SET. Resources: MEO, MDN, PMO, ENK, SD, JEMK, ALAK, RJL, RAT, JMM, MAMB, MIAK, MSdB, BV, WPA, PPvL, MMK. Data curation: MEO, ELMtH and SET. Writing—original draft preparation: ELMtH and SET. Writing—review and editing: JMPAvdR, EMGJdJ and SFKL, MEO, MDN, PMO, ENK, SD, JEMK, ALAK, RJL, RAT, JMM, MAMB, MIAK, MSdB, BV, WPA, PPvL, MMK. Visualization: ELMtH, SET. Supervision: JMPAvdR, EMGJdJ and SFKL. Project administration: JMPAvdR, EMGJdJ and SFKL. Funding acquisition: MEO, JMPAvdR, EMGJdJ.